The in vitro diagnostics market - France

The global in vitro diagnostics (IVD) market experienced significant growth, driven by demand for COVID-19 testing and the increasing prevalence of various health problems. North America held the largest market share in 2020 at 42.8%, but the Asia-Pacific region is expected to see the most dynamic growth. In Europe, the market jumped to 14.4 billion euros in 2020, and 20.7 billion euros in 2021, a trend paralleling the French market, which grew by 32% in 2020 and 22% in 2021. The market's rapid expansion can be attributed to rising healthcare spending, an ageing population and technological advances in in vitro diagnostics. In particular, the COVID-19 crisis has accelerated IVD consumption, with PCR tests becoming widely used and contributing significantly to market growth.

Dynamism and transformation of the in vitro diagnostics sector in the face of pandemic challenges

In the ever-changing landscape of the country's in vitro diagnostics (IVD) market, recent years have been marked by significant growth and transformation, particularly influenced by the COVID-19 health crisis. Traditionally, the in vitro diagnostics market encompasses a plethora of techniques and devices intended for diagnosis in medical laboratories, using human or animal samples. It is characterized by a diverse range of customers, mainly medical and hospital laboratories. The impact of the global pandemic cannot be ignored, which has particularly accelerated consumption of IVDs, given the critical role played by PCR tests during this period. Laboratories, which play a central role in the response to the pandemic, experienced a substantial increase in demand due to the soaring need for COVID-19 testing.

The market as a whole showed an impressive growth rate. The global IVD market grew by almost 80%, with an estimated value of between $90 and $95 billion by 2022. This robust growth is set to continue, reaching between $150 and $160 billion by 2030, with an average annual growth rate of around 7%. North America has traditionally dominated this landscape, but the winds of change are visible, with Europe and Asia-Pacific not far behind. The latter region in particular has shown an explosive growth trajectory, posting the highest compound annual growth rate (CAGR) forecasts for years to come. This testifies to the dynamic nature of the market and the shift in global economic weight towards Asia-Pacific markets.

In Europe, the French market is particularly important, being the second largest after Germany and accounting for over 10% of the European market. It enjoyed steady but moderate growth until the pandemic, which catalyzed an explosive increase in market value, with estimates reaching over 2.5 billion euros.

Worldwide, the market is segmented along traditional lines, with major international multi-sector groups such as Roche Diagnostics, Abbott and Thermo Fisher Diagnostics generating significant sales, demonstrating their strong presence in the field. Specialists in areas such as haemostasis and thrombosis (e.g. Diagnostica Stago) and rapid diagnostic tests (e.g. Biosynex) have also carved out substantial niches, underlining the diversity of needs and areas of interest in the IVD landscape.

In conclusion, driven primarily by the demand for diagnostic tests triggered by the pandemic, the in vitro diagnostics market has undergone remarkable expansion across the country and beyond.

Key players shaping the in vitro diagnostics landscape

The in vitro diagnostics (IVD) market has undergone remarkable growth and transformation, particularly accentuated by the advent of the COVID-19 pandemic. This era of change has been characterized by the emergence of key players, each making a significant contribution to the IVD ecosystem through their specialized offerings and innovations.

Below, we take a look at some of the most important entities at the forefront of this dynamic sector.

• Roche Diagnostics is a titan of the healthcare industry and a market leader in in vitro diagnostics. With a well-established reputation for continuous innovation, Roche provides a wide range of diagnostic tests and platforms that address a variety of medical conditions, including cancer, metabolic diseases and infectious diseases such as COVID-19. Its portfolio ranges from highly complex laboratory instruments to simple point-of-care tests, embodying its commitment to improving patient care by helping healthcare professionals gain actionable insights.
• Abbott Laboratories, a diversified healthcare conglomerate, offers a wide range of diagnostic solutions. Their expertise spans multiple segments of the IVD market, from basic laboratory diagnostics to molecular diagnostics and point-of-care testing. The company is known for its relentless pursuit of improving healthcare by providing reliable and accessible diagnostic technologies to communities worldwide.
• Thermo Fisher Scientific Thermo Fisher Scientific's role in the IVD market is underlined by its specialization in the supply of laboratory equipment, reagents and consumables. It meets the high demands of research and clinical laboratories, offering tools and services that facilitate the diagnostic process. Thermo Fisher's contributions to life sciences and healthcare are invaluable, with a focus on accelerating research and improving patient outcomes.
• Danaher Corporation is a global innovator in science and technology, and its various operating companies play a key role in the in vitro diagnostics market. The company's portfolio includes advanced diagnostic tests and systems that facilitate the diagnosis, monitoring and treatment of disease. Danaher's commitment to research and development enables it to remain at the forefront of advances in diagnostics.
• bioMérieux Specializing in microbiology, bioMérieux is a key player in providing diagnostic solutions for infectious diseases, cardiovascular emergencies and targeted cancer treatments. BioMérieux's commitment to public health is reflected in a range of systems that simplify and accelerate the testing process. BioMérieux products play a key role in clinical decisions worldwide, where accurate and timely diagnoses can have vital implications for patients.

Inforamtion

• Number of pages : 30 pages
• Format : Digital and PDF versions
• Last update : 18/10/2023

Summary and extracts

List of charts

• The European in vitro diagnostics market
• Breakdown of the global in vitro diagnostics market
• Sales in the in vitro diagnostics market
• Breakdown of IVD market share in Europe
• The French in vitro diagnostics market
• Health Expenditure of EU Countries
• Breakdown of CSBM by expenditure category
• Evolution of CSBM for analysis laboratories
• Consumption of medical care and goods
• Population projections to 2070
• Proportion of French population aged 65 and over
• Number of laboratories (companies) with at least one employee
• Ranking of leading medical biology laboratory groups by sales
• Changes in CSBM funding by social security for the analysis laboratory division
• Trend in household out-of-pocket expenses for analysis laboratory CSBM
• Annual change in the CSBM price index for analysis laboratories
• Covid-19 screening tests
• Proportion of antigenic tests among total PCR and antigenic tests by age group